Vontac 20 

Presentation: Vontac 20 is available as a film-coated tablet, with each tablet containing 20 mg of Vonoprazan (as fumarate). It is manufactured by Navana Pharmaceuticals Ltd. and typically comes in blister packs.

Indications: Vontac 20 is indicated for the treatment of:  

• Gastric ulcer  
• Duodenal ulcer  
• Reflux esophagitis  
• Prevention of recurrence of gastric or duodenal ulcer during low-dose aspirin administration.  
• Prevention of recurrence of gastric or duodenal ulcer duringNSAID administration.  
• Adjunct to Helicobacter pylori eradicationin specific conditions (gastric ulcer, duodenal ulcer, MALT lymphoma, idiopathic thrombocytopenic purpura, post-endoscopic resection of early-stage gastric cancer, or H. pylori gastritis).

Dosage and Administration:

• Gastric ulcer and duodenal ulcer: The usual adult dose is 20 mg once daily for 8 weeks (gastric ulcer) or 6 weeks (duodenal ulcer).
• Reflux esophagitis: The usual adult dose is 20 mg once daily for 4 weeks, which can be extended up to 8 weeks if needed. For maintenance therapy of reflux esophagitis with recurrence, the dose is 10 mg once daily, which may be increased to 20 mg if efficacy is inadequate.  
• Prevention of recurrence of gastric or duodenal ulcer during low-dose aspirin or NSAID administration:   The usual adult dose is 10 mg once daily.
• Helicobacter pylori eradication: The usual adult regimen is 20 mg of Vonoprazan, 750 mg of amoxicillin, and 200 mg of clarithromycin, all taken twice daily for 7 days. Alternative regimens may be used if the initial treatment fails.
• Vontac 20 can be taken without regard to food or the timing of meals.

Side Effects: The following side effects have been reported with the use of Vonoprazan:

• Diarrhea
• Constipation
• Drug hypersensitivity reactions (including rash and urticaria)
• Hepatotoxicity (liver damage)
• Jaundice (yellowing of the skin and eyes)
• Increased liver enzyme levels (AST, ALT, gamma-GTP)

Precautions:

• Vontac 20 is contraindicated in patients with hypersensitivity to Vonoprazan or any of its excipients, and in patients receiving atazanavir sulphate, nelfinavir, or rilpivirine hydrochloride.
• Caution is advised when consuming alcohol with Vonoprazan.
• Vonoprazan should be used during pregnancy only if the potential benefit justifies the risk to the fetus. It is advisable to avoid use in nursing mothers; if essential, breastfeeding should be discontinued.
• No dose adjustment is generally needed for patients with mild renal or hepatic impairment. Avoid use in moderate to severe hepatic impairment for reflux esophagitis treatment. Caution is advised in severe renal impairment for H. pylori eradication.
• Long-term use should be monitored closely, potentially with endoscopy. Maintenance therapy for reflux esophagitis should be limited to patients with recurring symptoms. Consider dose reduction or discontinuation in patients with sustained healing and no risk of recurrence.

Storage: Store below 30°C in a cool and dry place, protected from light. Keep out of reach of children.

Important Note: This information is for general knowledge and informational purposes only, and does not substitute professional medical advice. Always consult your doctor or pharmacist for specific instructions and guidance regarding your medication. They can assess your individual medical condition and provide the most appropriate advice.